IoM Report On Postmarketing Study Ethics Could Drive Broad Overhaul Of Informed Consent
This article was originally published in The Pink Sheet Daily
Executive Summary
Released in advance of Avandia advisory committee meeting, Institute of Medicine report provides a "conceptual framework" for deciding whether safety studies such as TIDE are ethical.
You may also be interested in...
Avandia Panel Wants Another Trial: Pipe Dream Or Post-market Benchmark?
Designed with complex, multi-variate statistics, an observational trial could determine the CV risk of rosiglitazone compared to other diabetes drugs, an advisory committee member suggests during the latest assessment of Avandia.
FDA Keeps Avandia On The Market But Looks To RECORD For More Clarity On CV Risk
Rosiglitazone will be available under a Risk Evaluation and Mitigation Strategy with restricted distribution pending an independent panel's re-adjudication of CV endpoints in the much-maligned, open-label RECORD study.
FDA Keeps Avandia On The Market But Looks To RECORD For More Clarity On CV Risk
Rosiglitazone will be available under a Risk Evaluation and Mitigation Strategy with restricted distribution pending an independent panel's re-adjudication of CV endpoints in the much-maligned, open-label RECORD study.